Veracyte (NASDAQ: VCYT) — Perfil da empresa, notícias e dados financeiros
Veracyte is a diagnostic company providing genomic solutions for early cancer detection and improved patient outcomes.
Veracyte
Veracyte (NASDAQ:VCYT) is a diagnostic company that focuses on delivering genomic solutions to improve patient outcomes and reduce healthcare costs. It specializes in developing tests for the early detection of cancer and other diseases, providing physicians with actionable insights for patient care. Veracyte's portfolio includes tests for thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis, among others. The company is committed to expanding its product range and enhancing its global presence through strategic partnerships and research advancements. Its operations span from the development and commercialization of its tests to collaborating with biopharmaceutical companies for companion diagnostic development. Veracyte aims to transform the diagnostic landscape by offering precise and minimally invasive tests, thereby enabling better disease management and treatment decisions for patients around the world.
Resumo
Operações
Produtos e/ou serviços de Veracyte
- Afirma Genomic Sequencing Classifier helps in identifying benign thyroid nodules to avoid unnecessary surgeries.
- Envisia Genomic Classifier aids in diagnosing interstitial lung diseases, including idiopathic pulmonary fibrosis.
- Percepta Genomic Sequencing Classifier is used for lung cancer risk assessment in patients with inconclusive lung nodules.
- Prosigna Breast Cancer Prognostic Gene Signature Assay provides information on the risk of recurrence for breast cancer patients.
- Decipher Prostate Genomic Classifier offers a risk assessment for prostate cancer progression and metastasis.
- LymphMark, a lymphoma subtyping test, helps in the diagnosis and treatment planning for B-cell lymphoma.
equipe executiva do Veracyte
- Marc A. StapleyCEO & Director
- Rebecca ChambersExecutive VP & CFO
- Phillip G. FebboChief Scientific & Medical Officer
- Annie McGuireExecutive VP, General Counsel & Head of Market Access
- John LeiteGlobal Chief Commercial Officer
- Keith GligorichSenior Vice President of Global Operations
- Jonathan WygantVP & Chief Accounting Officer
- Kevin Richard HaasChief Development & Technology Officer
- Steven FrenchSenior VP & Chief Information Officer
- Kelly GuraDirector of Investor Relations
Últimas notícias sobre a Veracyte
Principais indicadores financeiros
Resultados divulgados pela Veracyte, em USD.
- Cap. de mercado
- 4 bi
- Receita (TTM)
- 561,9 mi
- P/L
- 35.7
- LPA (diluído, TTM)
- 1.4
- Dividend yield
- —
- Margem de lucro
- 20.4%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 517,1 mi | 74,2 mi | 66,4 mi | |
| 445,8 mi | 16,1 mi | 24,1 mi | |
| 361,1 mi | -85,8 mi | -74,4 mi | |
| 296,5 mi | -41,1 mi | -36,6 mi |